Edition:
United States

Ardelyx Inc (ARDX.OQ)

ARDX.OQ on NASDAQ Stock Exchange Global Market

4.10USD
19 Sep 2018
Change (% chg)

$0.20 (+5.13%)
Prev Close
$3.90
Open
$3.95
Day's High
$4.22
Day's Low
$3.95
Volume
80,289
Avg. Vol
103,257
52-wk High
$8.60
52-wk Low
$3.60

Latest Key Developments (Source: Significant Developments)

Ardelyx Submits New Drug Application For IBS-C To FDA
Thursday, 13 Sep 2018 06:30am EDT 

Sept 13 (Reuters) - Ardelyx Inc ::ARDELYX SUBMITS NEW DRUG APPLICATION FOR U.S. MARKETING AUTHORIZATION OF TENAPANOR FOR IBS-C TO U.S. FOOD AND DRUG ADMINISTRATION.ARDELYX SUBMITS NEW DRUG APPLICATION FOR U.S. MARKETING AUTHORIZATION OF TENAPANOR FOR IBS-C TO U.S. FOOD AND DRUG ADMINISTRATION.ARDELYX INC - EXPECTS TO RECEIVE NOTIFICATION OF ACCEPTANCE OF FILING FOR SUBSTANTIVE REVIEW BEFORE END OF YEAR.  Full Article

Ardelyx Announces Proposed Public Offering Of Common Stock
Monday, 21 May 2018 04:01pm EDT 

May 21 (Reuters) - Ardelyx Inc ::ARDELYX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ARDELYX INC - STARTED UNDERWRITTEN PUBLIC OFFERING OF UP TO $50 MLN OF SHARES OF ITS COMMON STOCK.  Full Article

Ardelyx Reports Qtrly Loss Per Share $0.36
Tuesday, 8 May 2018 04:05pm EDT 

May 8 (Reuters) - Ardelyx Inc ::ARDELYX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.QTRLY LOSS PER SHARE $0.36.  Full Article

Knight Therapeutics Says ‍Will Have Exclusive Rights To Market And Sell Tenapanor In Canada​
Monday, 19 Mar 2018 06:30am EDT 

March 19 (Reuters) - Ardelyx Inc ::KNIGHT THERAPEUTICS - ‍LICENSE AGREEMENT WITH ARDELYX THAT PROVIDES KNIGHT WITH EXCLUSIVE RIGHTS TO COMMERCIALIZE TENAPANOR IN CANADA​.KNIGHT THERAPEUTICS - ‍WILL PAY UP TO C$25 MILLION IN TOTAL PAYMENTS INCLUDING AN UPFRONT PAYMENT AND DEVELOPMENT AND SALES MILESTONES.KNIGHT THERAPEUTICS INC - ‍KNIGHT WILL HAVE EXCLUSIVE RIGHTS TO MARKET AND SELL TENAPANOR IN CANADA​.  Full Article

Ardelyx Reports Qtrly Earnings Per Share $0.21
Wednesday, 14 Mar 2018 04:05pm EDT 

March 14 (Reuters) - Ardelyx Inc ::ARDELYX REPORTS 2017 FINANCIAL RESULTS AND APPOINTS INDUSTRY VETERAN, JAN LUNDBERG, PH.D., TO BOARD OF DIRECTORS.ARDELYX INC - QTRLY EARNINGS PER SHARE $0.21.  Full Article

Ardelyx Says Co Had About $134 Million In Cash
Monday, 8 Jan 2018 08:25am EST 

Jan 8 (Reuters) - Ardelyx Inc ::ARDELYX SAYS ON JAN 8, CO HAD ABOUT $134 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DEC 31, 2017 .  Full Article

Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C
Wednesday, 3 Jan 2018 06:30am EST 

Jan 3 (Reuters) - Ardelyx Inc ::ARDELYX SUCCESSFULLY COMPLETES T3MPO-3 SAFETY EXTENSION STUDY OF TENAPANOR FOR IBS-C.ARDELYX - ‍RESULTS FROM BOTH T3MPO-1 AND T3MPO-2 STUDIES, SAFETY DATA, SUPPORT CO'S PLANS TO SUBMIT FIRST NDA TO U.S. FDA FOR THE INDICATION IN H2 2018​.ARDELYX INC - RESULTS FROM T3MPO-3 SHOWED THAT TENAPANOR WAS WELL-TOLERATED AMONG 240 PATIENTS TREATED.  Full Article

Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China
Monday, 11 Dec 2017 06:00am EST 

Dec 11 (Reuters) - Ardelyx Inc ::Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China.Ardelyx - under terms of agreement, Ardelyx will receive upfront payment of $12 million, is eligible to receive additional milestones of up to $113 million.Ardelyx Inc - Fosun Pharma will have exclusive rights to market and sell Tenapanor in China.Ardelyx - under terms of agreement, co will receive tiered royalty payments on net sales from Tenapanor ranging from mid-teens to 20 percent.Ardelyx Inc - agreement also provides Fosun Pharma rights to commercialize Tenapanor for other indications for which it is approved in United States.  Full Article

Ardelyx Inc says has decided to discontinue development of RDX7675 for treatment of hyperkalemia​​
Tuesday, 21 Nov 2017 06:30am EST 

Nov 21 (Reuters) - Ardelyx Inc :Ardelyx announces updated development path for its cardiorenal pipeline.Ardelyx - second registration study for tenapanor for treatment of hyperphosphatemia will begin enrolling shortly​.Ardelyx - second registration study for tenapanor will begin enrolling shortly after having received feedback from U.S. FDA on trial design.Ardelyx Inc - ‍in addition, co reported clinically meaningful potassium lowering activity from its study for RDX7675 for treatment of hyperkalemia​.Says ‍however, company also observed an unexpected side effect of decreased serum bicarbonate​.Ardelyx Inc - ‍believes the side effect will limit commercial potential of RDX7675 and, as a result, has decided to discontinue development of RDX7675​.Ardelyx inc - ‍ Ardelyx will shift its hyperkalemia efforts to RDX013, its earlier-stage, small-molecule program​.Ardelyx Inc - the change will result in a cash savings of about $40 million to Ardelyx over next two years, extending co's operating runway into 2019​.  Full Article

Ardelyx qtrly ‍net loss per common share $0.44​
Tuesday, 7 Nov 2017 06:30am EST 

Nov 7 (Reuters) - Ardelyx Inc ::Ardelyx reports third quarter 2017 operating results and clinical progress.Ardelyx Inc - ‍as of September 30, 2017, Ardelyx had total capital resources including cash, cash equivalents and short-term investments of $129.3 million​.Ardelyx qtrly ‍net loss per common share $0.44​.Ardelyx - phase 3 registration study hit statistical significance for primary endpoint and all secondary endpoints for t3mpo-2.  Full Article